📢 Irradiate the whole pelvis in clinically node-negative high-risk localized prostate cancer yes/no? New systematic review and meta-analysis, evaluated 5 available phase III randomized trials, including 5,172 patients, comparing whole-pelvic radiotherapy (WPRT) versus prostate-only radiotherapy (PORT). 🔹 No overall survival benefit was observed with WPRT: HR 1.07 (95% CI 0.94–1.21). 🔹 The apparent benefit in biochemical/progression-free and metastasis-free survival was largely driven by the POP-RT trial and was no longer evident when this study was excluded. 🔹 WPRT was associated with a modest increase in late grade ≥2 GU/GI toxicity, without a meaningful excess of severe events with modern radiotherapy techniques. 👉 Key message: current randomized evidence does not support routine elective pelvic irradiation for all cN0 high-risk patients. “Alone we can do so little; together, we can do so much” congratulations to all the team 💪 #ProstateCancer @josedsh @fcounago @PedrodePablos1 sciencedirect.com/science/ar…

Long live DRE, die DRE ☝️ DRE may be dying as a screening test, but it is far from dead. The latest evidence supports removing DRE from routine screening in asymptomatic men, yet it still retains an important role in clinical staging until imaging fully replaces it sciencedirect.com/science/ar…